These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

918 related articles for article (PubMed ID: 18057140)

  • 1. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.
    Kearns AE; Khosla S; Kostenuik PJ
    Endocr Rev; 2008 Apr; 29(2):155-92. PubMed ID: 18057140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [RANKL and OPG regulation on bone remodeling].
    Zhao Y; Cai Y; Wang YN
    Shanghai Kou Qiang Yi Xue; 2010 Aug; 19(4):443-6. PubMed ID: 20871967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
    Vega D; Maalouf NM; Sakhaee K
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4514-21. PubMed ID: 17895323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functions of RANKL/RANK/OPG in bone modeling and remodeling.
    Boyce BF; Xing L
    Arch Biochem Biophys; 2008 May; 473(2):139-46. PubMed ID: 18395508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal and extraskeletal actions of denosumab.
    Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
    Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key roles of the OPG-RANK-RANKL system in bone oncology.
    Baud'huin M; Duplomb L; Ruiz Velasco C; Fortun Y; Heymann D; Padrines M
    Expert Rev Anticancer Ther; 2007 Feb; 7(2):221-32. PubMed ID: 17288531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases.
    Hofbauer LC; Schoppet M
    JAMA; 2004 Jul; 292(4):490-5. PubMed ID: 15280347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
    Hofbauer LC; Heufelder AE
    J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The RANKL/RANK/OPG pathway.
    Boyce BF; Xing L
    Curr Osteoporos Rep; 2007 Sep; 5(3):98-104. PubMed ID: 17925190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.
    Theoleyre S; Wittrant Y; Tat SK; Fortun Y; Redini F; Heymann D
    Cytokine Growth Factor Rev; 2004 Dec; 15(6):457-75. PubMed ID: 15561602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications].
    Clézardin P
    Bull Cancer; 2011 Jul; 98(7):837-46. PubMed ID: 21700551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss.
    Trouvin AP; Goëb V
    Clin Interv Aging; 2010 Nov; 5():345-54. PubMed ID: 21228900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
    Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
    Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RANK/RANKL/OPG role in distraction osteogenesis.
    Pérez-Sayáns M; Somoza-Martín JM; Barros-Angueira F; Rey JM; García-García A
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 May; 109(5):679-86. PubMed ID: 20163972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
    Kostenuik PJ; Shalhoub V
    Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases.
    Delmas PD
    J Clin Densitom; 2008; 11(2):325-38. PubMed ID: 18375161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biology of RANK, RANKL, and osteoprotegerin.
    Boyce BF; Xing L
    Arthritis Res Ther; 2007; 9 Suppl 1(Suppl 1):S1. PubMed ID: 17634140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of RANKL in bone diseases.
    Anandarajah AP
    Trends Endocrinol Metab; 2009 Mar; 20(2):88-94. PubMed ID: 19185505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
    Hofbauer LC; Neubauer A; Heufelder AE
    Cancer; 2001 Aug; 92(3):460-70. PubMed ID: 11505389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.